NDLI: CAR-armored-cell therapy in solid tumor treatment

Content Provider	Springer Nature : BioMed Central
Author	Liu, Yan Xiao, Lin Yang, Mingxuan Chen, Xuemei Liu, Hongyue Wang, Quanxing Guo, Meng Luo, Jianhua
Abstract	Over the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a revolutionary immunotherapeutic approach to combat cancer. This therapy constructs a CAR on the surface of T cells through genetic engineering techniques. The CAR is formed from a combination of antibody-derived or ligand-derived domains and T-cell receptor (TCR) domains. This enables T cells to specifically bind to and activate against tumor cells. However, the efficacy of CAR-T cells in solid tumors remains inconclusive due to several challenges such as poor tumor trafficking, infiltration, and the immunosuppressive tumor microenvironment (TME). In response, CAR natural killer (CAR-NK) and CAR macrophages (CAR-M) have been developed as complementary strategies for solid tumors. CAR-NK cells do not require HLA compatibility, demonstrate reduced toxicity, and are thus seen as potential substitutes for CAR-T cells. Furthermore, CAR-M immunotherapy is also being researched and has shown phagocytic capabilities and tumor-antigen presentation. This study discusses the features, advantages, and limitations of CAR-T, CAR-NK, and CAR-M cells in the treatment of solid tumors and suggests prospective solutions for enhancing the efficacy of CAR host-cell-based immunotherapy.
Related Links	https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/s12967-024-05903-3.pdf
Ending Page	15
Page Count	15
Starting Page	1
File Format	HTM / HTML
ISSN	14795876
DOI	10.1186/s12967-024-05903-3
Journal	Journal of Translational Medicine
Issue Number	1
Volume Number	22
Language	English
Publisher	BioMed Central
Publisher Date	2024-11-28
Access Restriction	Open
Subject Keyword	Biomedicine Medicine Public Health CAR-T CAR-NK CAR-M Solid tumor Medicine/Public Health
Content Type	Text
Resource Type	Review
Subject	Biochemistry, Genetics and Molecular Biology Medicine
Journal Impact Factor	6.1/2023
5-Year Journal Impact Factor	6.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy

CD8+ T cell-based cancer immunotherapy

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

DNTGF-βR armored CAR-T cell therapy against tumors from bench to bedside

Recent Advances in CAR-Based Solid Tumor Immunotherapy.

Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment

Correction: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Targeting macrophages: a novel treatment strategy in solid tumors

CAR-armored-cell therapy in solid tumor treatment

Similar Documents

Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy

CD8+ T cell-based cancer immunotherapy

CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

DNTGF-βR armored CAR-T cell therapy against tumors from bench to bedside

Recent Advances in CAR-Based Solid Tumor Immunotherapy.

Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment

Correction: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Targeting macrophages: a novel treatment strategy in solid tumors

CAR-armored-cell therapy in solid tumor treatment